Table VII.
The most common combinations of DDIs of clinical significance level D on hospital discharge
| Drug-drug interaction | N (%) | Description |
|---|---|---|
| Total DDIs of clinical significance level D at discharge n = 352 | ||
| β-Blocker–α receptor antagonist | 43 (12.2) | β-Blockers may enhance the orthostatic hypotensive effect of α1-blockers. |
| Calcium carbonate–bisphosphonates | 25 (7.1) | Calcium salts may reduce the serum concentration of bisphosphonate derivatives. |
| ACE inhibitor–allopurinol | 21 (6.0) | ACE inhibitors may enhance the potential for allergic or hypersensitivity reactions to allopurinol. |
| ACE inhibitor (except ramipril)–calcium carbonate | 20 (5.7) | Antacids may reduce the serum concentration of ACE inhibitors. |
| Levothyroxine–warfarin | 14 (4.0) | Thyroid products may enhance the anticoagulant effect of vitamin K antagonists. |
| Methylprednisolone–calcium carbonate | 13 (3.7) | Antacids may reduce the bioavailability of corticosteroids (oral). |
| NSAIDs–loop diuretic | 13 (3.7) | Nonsteroidal anti-inflammatory agents may diminish the diuretic effect of loop diuretics. |
| Proton pump inhibitor (esomeprazole, pantoprazole)–clopidogrel | 12 (3.4) | Esomeprazole and pantoprazole may reduce serum concentrations of the active metabolite(s) of clopidogrel. |
| Allopurinol–warfarin | 12 (3.4) | Allopurinol may enhance the anticoagulant effect of vitamin K antagonists. |
| Aspirin–warfarin | 11 (3.1) | Salicylates may enhance the anticoagulant effect of vitamin K antagonists. |
| Theophylline–benzodiazepines | 11 (3.1) | Theophylline derivatives may diminish the therapeutic effect of benzodiazepines. |